Traws Pharma, Inc. - Common Stock TRAW 深 沪
等待开盘 11-06 09:30:00 美东时间
2.17
-0.030
-1.36%
华盛通- 最 高2.29
- 今 开2.22
- 成交量 4.51万股
- 最 低 2.11
- 昨 收 2.20
- 总市值 1532.84万
- 52周最高 19.44
- 市盈率 静 --
- 换手率 0.64%
- 52周最低 0.97
- 委 比 92.31%
- 总股本 706.38万
- 历史最高 1751062.50
- 量 比 0.23
- 振 幅 8.18%
- 历史最低 0.97
- 每 手 1
- 风险率 2.35%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Traws Pharma’s TRX-100 Study: A Potential Game-Changer in Pharmacokinetics
Traws Pharma, Inc. (($TRAW)) announced an update on their ongoing clinical stud...
10-28 00:59
Traws Pharma Approves Executive Stock Options Grant
Traws Pharma ( ($TRAW) ) has provided an update. On October 12, 2025, Traws Pha...
10-18 05:28
Traws Pharma Adds John Leaman, MD, as Independent Director and Formalizes Appointments of Two Key Executives
Traws Pharma, Inc. has appointed John Leaman, MD, as an independent director, effective October 1, 2025. The company also removed the interim titles of its executives, Iain Dukes and Charles Parker, who are now CEO and CFO, respectively. Dr. Leaman brings extensive experience in finance and corporate strategy. The company is advancing ratutrelvir, a COVID-19 treatment, and tivoxavir marboxil, a potential bird flu and seasonal influenza therapy, w...
10-06 11:00
Annovis Bio appoints CFO
Clinical drug platform company Annovis Bio (NYSE:ANVS) announced on Thursday the appointment of Mark Guerin as CFO. Guerin has previously served at Onconova Therapeutics (TRAW), now known as Traws Pha...
09-25 19:55
Traws Pharma Receives HREC Approval To Initiate Phase 2 COVID Studies Of Ratutrelvir, A Ritonavir-Free Treatment, With Results Expected By Year-End 2025
Non-inferiority trial to assess safety and efficacy, including rates of disease rebound and incidence of Long COVID development of ratutrelvir, a ritonavir-free treatment, compared to PAXLOVIDSeparate single-arm trial
08-18 19:08
Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025
Traws Pharma announced the launch of Phase 2 trials for ratutrelvir, a ritonavir-free COVID treatment, to compare its safety and efficacy with Paxlovid. The trials will assess disease rebound rates, Long COVID incidence, and safety in Paxlovid-ineligible patients. Top-line results are expected by year-end 2025. Ratutrelvir aims to overcome shortcomings of current treatments, including unfavorable drug interactions and limited efficacy, with once-...
08-18 11:00
Traws Pharma Q2 2025 GAAP EPS $(0.11) Up From $(20.52) YoY, Sales $2.733M Up From $57.000K YoY
Traws Pharma (NASDAQ:TRAW) reported quarterly losses of $(0.11) per share. This is a 99.46 percent increase over losses of $(20.52) per share from the same period last year. The company reported $2.733 million in sales
08-14 19:04
Earnings Scheduled For August 14, 2025
Companies Reporting Before The Bell • Sunlands Technology (NYSE:STG) is likely ...
08-14 16:32
Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025
Traws Pharma, a clinical-stage biopharmaceutical company focused on novel therapies for respiratory viral diseases, will host a conference call on August 14, 2025, at 8:30 AM ET to discuss Q2 2025 financial results and recent progress. The call will be accessible via telephone or webcast, with replay available later. Traws is advancing antiviral agents targeting bird flu, seasonal influenza, and COVID-19, including Tivoxavir marboxil and Ratutrel...
08-08 11:00
